The cure for Multiple Sclerosis has once again been put to the spotlight as Merck KGaA, Darmstadt, Germany, a leading science and technology company, operating as EMD Serono in Canada has recently announced the findings obtained from their comprehensive study. The analysis has shown that Cladribine Tablets has demonstrated promising results as it has been found to have reduced the annualized rate of brain volume loss, which is usually referred to as brain atrophy, as compared with placebo in patients with relapsing remitting multiple sclerosis (RRMS). Experts said that the primary endpoint was the relapse rate of over 96 weeks; while the secondary endpoints were noted to have included MRI endpoints, proportion of subjects relapse-free, as well as disability progression at 96 weeks.
Cladribine Tablets In Multiple Sclerosis
Long before, Multiple sclerosis (MS) has been regarded as a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. According to reports revealed by CNW Online, experts have revealed that Cladribine Tablets is basically an investigational short-course oral therapy that selectively and periodically targets lymphocytes that are thought to be integral to the pathological process of MS. As of the press time, Cladribine Tablets is under clinical investigation and has not yet been approved for the treatment for any use in the United States, Canada and Europe.
The Study Involving Cladribine Tablets
Meanwhile, in one of her statements reported by MPR Online, study lead author and associate professor of neurology at the University of Siena, Nicola De Stefano said that the analysis obtained in the their study plays an important role because it confirms the link between reduced brain atrophy and reduced disability progression found in the study. The associate professor also said that the findings support the existing research which indicates that increased brain volume loss over time is associated with worse clinical outcomes, such as increased disability progression and cognitive changes, particularly in MS patients.
Furthermore, it was found that Cladribine Tablets are still in the process of being evaluated in a clinical development program and are yet to be approved for the treatment of any condition in the U.S. Additionally, with regards to the findings from the study, Merck CMO Steven Hildemann said that the findings will be able to make this investigational therapy available for patients living with relapse remitting multiple sclerosis.